B. Riley Predicts Harrow’s Q3 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Stock analysts at B. Riley lifted their Q3 2025 earnings per share estimates for Harrow in a research report issued on Thursday, August 21st. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of $0.29 for the quarter, up from their previous estimate of $0.25. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s Q4 2025 earnings at $0.65 EPS and FY2027 earnings at $4.21 EPS.

A number of other equities analysts have also recently weighed in on the stock. Zacks Research raised shares of Harrow from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. BTIG Research lifted their price objective on shares of Harrow from $62.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Cantor Fitzgerald assumed coverage on shares of Harrow in a report on Friday, July 11th. They issued an “overweight” rating and a $76.00 target price on the stock. William Blair began coverage on shares of Harrow in a report on Tuesday, June 10th. They set an “outperform” rating on the stock. Finally, HC Wainwright upped their price target on shares of Harrow from $60.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat, Harrow currently has a consensus rating of “Buy” and a consensus price target of $64.67.

Harrow Stock Up 2.5%

HROW opened at $39.12 on Friday. The company has a market cap of $1.45 billion, a PE ratio of -156.48 and a beta of 0.41. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. Harrow has a twelve month low of $20.85 and a twelve month high of $59.23. The company has a 50-day moving average price of $33.93 and a 200 day moving average price of $29.16.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The business had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its holdings in shares of Harrow by 345.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after acquiring an additional 2,615 shares during the period. Engineers Gate Manager LP grew its stake in shares of Harrow by 194.7% in the 2nd quarter. Engineers Gate Manager LP now owns 35,565 shares of the company’s stock worth $1,086,000 after purchasing an additional 23,495 shares during the last quarter. Bank of America Corp DE increased its position in shares of Harrow by 266.8% in the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after acquiring an additional 155,258 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Harrow in the second quarter worth approximately $48,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Harrow by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after purchasing an additional 341 shares during the period. 72.76% of the stock is currently owned by institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.